1. Home
  2. BVFL vs AGEN Comparison

BVFL vs AGEN Comparison

Compare BVFL & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BV Financial Inc.

BVFL

BV Financial Inc.

N/A

Current Price

$20.48

Market Cap

168.6M

Sector

Finance

ML Signal

N/A

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$5.98

Market Cap

208.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BVFL
AGEN
Founded
1873
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
168.6M
208.2M
IPO Year
2023
1999

Fundamental Metrics

Financial Performance
Metric
BVFL
AGEN
Price
$20.48
$5.98
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
15.4K
8.2M
Earning Date
04-24-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
31.19
100.00
EPS
0.13
1.02
Revenue
N/A
$42,877,086.00
Revenue This Year
N/A
$107.63
Revenue Next Year
N/A
N/A
P/E Ratio
$159.08
$6.11
Revenue Growth
N/A
89.95
52 Week Low
$14.60
$2.71
52 Week High
$22.17
$8.70

Technical Indicators

Market Signals
Indicator
BVFL
AGEN
Relative Strength Index (RSI) 44.88 68.65
Support Level $20.24 $3.16
Resistance Level $22.00 $8.70
Average True Range (ATR) 0.76 0.77
MACD -0.16 0.18
Stochastic Oscillator 40.88 50.00

Price Performance

Historical Comparison
BVFL
AGEN

About BVFL BV Financial Inc.

BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. The company offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, and business checking and certificates of deposit and IRA certificates of deposit. The Company's sources of revenue are derived from interest and dividends earned on loans and investment securities.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: